Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


U.S. FDA Requests Halt To CytRx Trial Of Lou Gehrig’s Disease Drug (India)

This article was originally published in PharmAsia News

Executive Summary

The U.S. FDA has asked India's CytRx to stop its Phase II trial of a Lou Gehrig-disease drug because the company lacks the data to continue. The U.S. agency asked the company for more analysis of toxicology studies performed on animals for the arimoclomol drug aimed at treating amyotropic lateral sclerosis. CytRx said there was no data in any of the trials related to safety in humans, and the firm has asked for clarification. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts